Anterix (ATEX) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Anterix (ATEX) over the last 13 years, with Q4 2025 value amounting to $1.4 million.
- Anterix's Cost of Revenue rose 993.12% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.0 million, marking a year-over-year decrease of 430.81%. This contributed to the annual value of $6.1 million for FY2025, which is 732.48% up from last year.
- Per Anterix's latest filing, its Cost of Revenue stood at $1.4 million for Q4 2025, which was up 993.12% from $1.4 million recorded in Q3 2025.
- In the past 5 years, Anterix's Cost of Revenue registered a high of $1.9 million during Q1 2023, and its lowest value of $872000.0 during Q1 2021.
- Its 5-year average for Cost of Revenue is $1.4 million, with a median of $1.3 million in 2023.
- Over the last 5 years, Anterix's Cost of Revenue had its largest YoY gain of 8683.43% in 2021, and its largest YoY loss of 2303.62% in 2021.
- Quarter analysis of 5 years shows Anterix's Cost of Revenue stood at $1.3 million in 2021, then grew by 9.66% to $1.4 million in 2022, then decreased by 0.36% to $1.4 million in 2023, then dropped by 5.14% to $1.3 million in 2024, then rose by 9.93% to $1.4 million in 2025.
- Its Cost of Revenue was $1.4 million in Q4 2025, compared to $1.4 million in Q3 2025 and $1.5 million in Q2 2025.